Hormonal therapy for patients with advanced adenocarcinoma of the prostate: Is there a role for discontinuing treatment after prolonged androgen suppression?

Urology

Volumn 61, Issue 4, 2003, Pages 770-773

  Pedraza, Roberto ^a   Kwart, Arnold M ^a  

^a WASHINGTON HOSPITAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; GONADORELIN AGONIST; LUTEINIZING HORMONE; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

ADVANCED CANCER; AGED; ANDROGEN THERAPY; ARTICLE; BLOOD ANALYSIS; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CASE REPORT; CELL FUNCTION; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; HUMAN; HYPOTHALAMUS HYPOPHYSIS GONAD SYSTEM; LEYDIG CELL; LUTEINIZING HORMONE BLOOD LEVEL; MALE; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATECTOMY; PROTEIN BLOOD LEVEL; TESTOSTERONE BLOOD LEVEL; TREATMENT WITHDRAWAL;

EID: 0037381996     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(02)02441-X     Document Type: Article

References (9)

1. Hall M.C., Fritzsch R.J., Sagalowsky A.I. Prospective determination of the hormonal response after cessation of luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer. Urology. 53:1999;898-903.
2. Oefelein M.G. Time to normalization of serum testosterone after 3-month luteinizing hormone-releasing hormone agonist administered in the neoadjuvant setting implications for dosing schedule and neoadjuvant study consideration. J Urol. 160:1998;1685-1688.
3. Daehlin L., Tomic R., Damber J.E. Depressed testosterone release from testicular tissue in vitro after withdrawal of estrogen treatment in patients with prostatic carcinoma. Scand J Urol Nephrol. 22:1988;11-13.
4. Daehlin L. On the effects of estrogen in the male some effects of different estrogenic substances in rats and men with prostatic carcinoma. Scand J Urol Nephrol. 91:1985;1-44.
5. Payer A.F., Meyer W.J. III, Walker P.A. The ultrastructural response to human Leydig cells to exogenous estrogens. Andrologia. 11:1979;423-436.
6. Tomic R., Bergman B., Damber J.E. Testicular endocrine function after withdrawal of estrogen treatment in patients with carcinoma of the prostate. Br J Urol. 55:1983;42-47.
7. Tomic R., Danber J.E., Bergman B. Endocrine effects of estrogen withdrawal in long-term treated patients with prostatic adenocarcinoma. Eur Urol. 14:1988;6-8.
8. Oefelein M.G. Serum testosterone-based luteinizing hormone-releasing hormone agonist redosing schedule for chronic androgen ablation a phase I assessment. Urology. 54:1999;694-699.
9. Gleave M., Bruchovsky N., Goldenberg S.L., et al. Intermittent androgen suppression for prostate cancer rationale and clinical experience. Eur Urol. 34:(suppl 3):1998;37-41.